Elon Musk’s brain-chip startup, Neuralink, has made a significant stride with its Blindsight implant, which has been awarded the FDA’s breakthrough device designation. The implant aims to restore vision, even for individuals who have lost both eyes and their optic nerve. This designation is reserved for medical devices addressing life-threatening conditions, allowing for expedited development and review processes.
Blindsight: A Revolutionary Vision-Restoring Implant
The Blindsight implant functions by placing a microelectrode array into the visual cortex of the brain. This array activates neurons, creating a visual image for the patient. According to Musk, even individuals who were blind from birth could experience sight through the device. Initially, the vision will be low-resolution, but Musk envisions a future where the technology could surpass natural vision, potentially allowing users to see in infrared, ultraviolet, or radar wavelengths.
Future Human Trials and Neuralink’s Broader Vision
Neuralink has not yet announced when human trials for the Blindsight device will begin. However, the company is currently seeking participants for its PRIME study, focused on giving individuals with quadriplegia the ability to use digital devices by thought alone. Earlier this year, Neuralink successfully implanted a brain-computer interface device in its second patient, who has since used it for activities such as playing video games and designing 3D objects.
A New Era for Brain-Computer Interface Technology
Neuralink aims to create a generalized brain-computer interface (BCI) platform capable of interfacing with every aspect of the human brain. Other companies in the field, such as Neurable, are also exploring neurotechnology applications, expanding the possibilities for brain health and cognitive performance improvements.
With Blindsight, Neuralink is pushing the boundaries of restorative vision and brain-computer interfaces, positioning itself at the forefront of medical and technological innovation.
